(Total Views: 562)
Posted On: 09/29/2021 6:30:30 AM
Post# of 154115
The Activist Group’s Continued Attempts to Link CytoDyn to IncellDx Are Troubling
Patient safety and data accuracy will always remain CytoDyn’s main concern. Based on its first-hand experience in working with IncellDx, CytoDyn sees any relationship between IncellDx and the Company as a liability for shareholders rather than an asset. That is why the Activist Group’s suggestion to define cancer targets using the IncellDx H-Scoring system is misguided – particularly since the Group proposes that CytoDyn license this system from IncellDx. Consider the following:
It is clearly a direct conflict of interest for Dr. Bruce Patterson to continuously seek to force a relationship between IncellDx and CytoDyn while trying to gain a seat on the Board of Directors of CytoDyn.
Together with his wife, Dr. Patterson owns approximately 34% of IncellDx and Jeff Beaty, another member of the Activist Group, owns about 2.3% of IncellDx.
Patient safety and data accuracy will always remain CytoDyn’s main concern. Based on its first-hand experience in working with IncellDx, CytoDyn sees any relationship between IncellDx and the Company as a liability for shareholders rather than an asset. That is why the Activist Group’s suggestion to define cancer targets using the IncellDx H-Scoring system is misguided – particularly since the Group proposes that CytoDyn license this system from IncellDx. Consider the following:
It is clearly a direct conflict of interest for Dr. Bruce Patterson to continuously seek to force a relationship between IncellDx and CytoDyn while trying to gain a seat on the Board of Directors of CytoDyn.
Together with his wife, Dr. Patterson owns approximately 34% of IncellDx and Jeff Beaty, another member of the Activist Group, owns about 2.3% of IncellDx.
(5)
(0)
